Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Prostate cancer

Searching for bone metastases—how, when and why?

Bone metastases from prostate cancer are detected with staging bone scans. New research supports existing guidelines on the appropriate referral criteria for bone scans and shows that a specific subgroup of patients with prostate cancer who are at low risk of bone metastases do not require a staging bone scan.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Mohler, J. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J. Natl Compr. Canc. Netw. 8, 162–200 (2010).

    Article  CAS  PubMed  Google Scholar 

  2. McArthur, C., McLaughlin, G. & Meddings, R. N. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients. Br. J. Radiol. doi:10.1259/bjr/79184355.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. 3. Lecouvet, F. E. et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J. Clin. Oncol. 25, 3281–3287 (2007).

    Article  PubMed  Google Scholar 

  4. Smith, M. R., Cook, R., Lee, K. A. & Nelson, J. B. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer doi:10.1002/cncr.25762.

    Article  PubMed  Google Scholar 

  5. Smith, M. R. et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J. Clin. Oncol. 23, 2918–2925 (2005).

    Article  PubMed  Google Scholar 

  6. Coleman, R. et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit. Rev. Oncol. Hematol. doi:10.1016/j.critrevonc.2011.02.005.

    Article  PubMed  Google Scholar 

  7. Saad, F., Eastham, J. A. & Smith, M. R. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol. Oncol. doi:10.1016/j.urolonc.2010.08.007.

    Article  CAS  PubMed  Google Scholar 

  8. Saad, F. & Eastham, J. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer. Urology 76, 1175–1181 (2010).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Saad, F. Searching for bone metastases—how, when and why?. Nat Rev Urol 8, 358–359 (2011). https://doi.org/10.1038/nrurol.2011.70

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2011.70

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing